Key Points
- COO Cortney Caudill sold shares: Caudill sold 8,857 shares on March 10 at an average of $67.64 for ~$599,087 and had sold 20,000 shares on March 9 at $67.80 (~$1.356M), reducing her stake by 55.66% to 7,055 shares.
- Mixed quarterly results: Halozyme reported an EPS loss of ($0.24) versus a $1.92 consensus (a significant miss) while revenue of $451.77M beat estimates and rose 51.6% year-over-year.
- Market and analyst backdrop: The stock (market cap ~$8B) trades in a one-year range of $47.50–$82.22 and carries an average analyst rating of "Hold" with a consensus target price of $78.56.
Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) COO Cortney Caudill sold 8,857 shares of the firm's stock in a transaction dated Tuesday, March 10th. The stock was sold at an average price of $67.64, for a total transaction of $599,087.48. Following the sale, the chief operating officer owned 7,055 shares of the company's stock, valued at approximately $477,200.20. The trade was a 55.66% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Cortney Caudill also recently made the following trade(s):
- On Monday, March 9th, Cortney Caudill sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $67.80, for a total transaction of $1,356,000.00.
Halozyme Therapeutics Stock Down 0.5%
HALO stock opened at $67.81 on Wednesday. Halozyme Therapeutics, Inc. has a one year low of $47.50 and a one year high of $82.22. The firm has a market cap of $8.00 billion, a PE ratio of 27.23, a PEG ratio of 0.28 and a beta of 0.98. The firm's 50 day moving average price is $72.64 and its 200-day moving average price is $70.67. The company has a debt-to-equity ratio of 43.89, a quick ratio of 3.66 and a current ratio of 4.66.
Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its quarterly earnings data on Tuesday, February 17th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of $1.92 by ($2.16). The business had revenue of $451.77 million during the quarter, compared to analysts' expectations of $446.13 million. Halozyme Therapeutics had a return on equity of 136.12% and a net margin of 22.69%.The company's revenue was up 51.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.26 earnings per share. On average, equities research analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.
Wall Street Analyst Weigh In
A number of analysts recently issued reports on the company. HC Wainwright reissued a "buy" rating on shares of Halozyme Therapeutics in a research report on Thursday, January 29th. Weiss Ratings cut shares of Halozyme Therapeutics from a "buy (b-)" rating to a "hold (c)" rating in a research report on Tuesday, February 24th. Wells Fargo & Company lifted their price target on shares of Halozyme Therapeutics from $65.00 to $75.00 and gave the company an "equal weight" rating in a research report on Thursday, February 19th. Wall Street Zen downgraded shares of Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Saturday, February 21st. Finally, Benchmark upped their price objective on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a "buy" rating in a report on Thursday, February 19th. Six equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $78.56.
Read Our Latest Analysis on HALO
Institutional Trading of Halozyme Therapeutics
Several hedge funds have recently modified their holdings of the stock. CWM LLC increased its holdings in Halozyme Therapeutics by 2,136.0% during the 3rd quarter. CWM LLC now owns 23,881 shares of the biopharmaceutical company's stock worth $1,751,000 after purchasing an additional 22,813 shares during the period. Arbor Investment Advisors LLC purchased a new position in shares of Halozyme Therapeutics in the 3rd quarter valued at about $1,316,000. Monument Capital Management purchased a new position in shares of Halozyme Therapeutics in the 3rd quarter valued at about $2,015,000. Pacer Advisors Inc. grew its position in shares of Halozyme Therapeutics by 2,054.7% during the third quarter. Pacer Advisors Inc. now owns 478,874 shares of the biopharmaceutical company's stock worth $35,121,000 after buying an additional 456,649 shares in the last quarter. Finally, Cardinal Capital Management purchased a new stake in shares of Halozyme Therapeutics during the third quarter worth approximately $1,303,000. 97.79% of the stock is currently owned by institutional investors and hedge funds.
Halozyme Therapeutics Company Profile
(
Get Free Report)
Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company's core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.
The company's flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
